Neurotech platform delivers biological agent over extended period to slow progression of retinal-based diseases

Video

Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research.

Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director, during the New Horizons Forum at the 2022 Glaucoma 360 meeting

Recent Videos
This series features 1 KOL.
This series features 1 KOL.
This series features 1 KOL.
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.